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ABSTRACT 
The commonest cause of acute myocardial infarction 
involves the rupture or erosion of vulnerable athero- 
sclerotic plaques followed by aggregation of platelets 
and subsequent thrombus formation, leading to par- 
tial or complete epicardial coronary arterial occlusion. 
Over the last 25 years, advancement in therapeutic 
options for acute myocardial infarction has resulted 
in substantial improvement in morbidity and mortal- 
ity. As a result, the absolute risk reduction of in-hos- 
pital deaths for patients presenting with STEMI has 
been on the decline in the last decade. The focus of 
the treatment for acute myocardial infarction invol- 
ves achieving epicardial and microvascular patency, 
prevention of recurrent ischaemic events while bal- 
ancing the risk of bleeding. This involves antiplatelet 
and antithrombotic therapies or fibrinolytic agents 
when timely performance of primary percutaneous 
coronary intervention is not possible. We review the 
evolution of treatment strategies for STEMI that has 
contributed to the improvement in patient outcome.  
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1. BACKGROUND 
Pathophysiology of Acute Myocardial Infarction 
The commonest cause of acute myocardial infarction in- 
volves the rupture or erosion of vulnerable atheroscle- 
rotic plaques followed by aggregation of platelets and 
subsequent thrombus formation, leading to partial or 
complete epicardial coronary arterial occlusion [1,2]. Mi- 
crocirculatory perfusion is compromised by this throm- 
botic process due to reduced coronary artery blood flow 
through fixed epicardial stenoses, as well as distal em- 
bolisation of thrombus. During the early phase of coro- 
nary occlusion, the discrepancy between myocardial oxy- 
gen supply and demand results in myocardial ischaemia. 
If ischaemia persists, myocardial injury becomes irre- 
versible, resulting in myocardial necrosis. This typically 
extends from the subendocardium towards the subepi- 
cardium. Reimer and Jennings [3] first described the 
concept of “wavefront phenomenon of myocardial death”. 
The major determinant of final infarct size, transmural 
necrosis and microvascular damage is the duration of 
ischaemia. Previous studies have validated the associa- 
tion between increased duration of ischaemia with worse 
myocardial perfusion and increased mortality rate in pa- 
tients treated with fibrinolysis [4] and primary percuta- 
neous coronary intervention (primary-PCI) [5]. Therefore, 
the cornerstone for management of ST-segment elevation 
myocardial infarction (STEMI) involves:  
1) Rapid restoration of epicardial and microvascular 
blood flow utilising combination of pharmacological and 
percutaneous intervention;  
2) Prevention of recurrent ischaemic events with anti- 
thrombotic and antiplatelet therapies;  
3) Reducing effect of myocardial necrosis;  
4) Reducing in-hospital and out-of-hospital complica- 
tions; 
5) Preventing future events. 
Over the last 25 years, therapeutic options for treat- 
ment of patients with myocardial infarction have improved 
substantially. As a result, the absolute risk reduction of 
in-hospital deaths for patients presenting with STEMI 
has been on the decline in the last decade [6]. We review 
the evolution of treatment strategies for STEMI that has 
contributed to the improvement in patient outcome. 
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2. REPERFUSION FOR STEMI 
The main goal is prompt reperfusion of myocardial blood 
flow which has been shown to reduce mortality [7]. The 
options include pharmacological reperfusion with fibri- 
nolytic agents and primary-PCI. In major centres with 
primary-PCI capability, primary-PCI has become the 
standard of care. However, fibrinolysis remains the most 
viable treatment option in patients presenting to non-PCI 
capable hospitals whose transport time to a PCI-capable 
hospital is greater than 120 minutes [8]. 
2.1. Fibrinolysis 
A major breakthrough leading to considerable improve- 
ment in survival after STEMI was heralded by the intro- 
duction of fibrinolysis in the 1990’s as a pharmacological 
reperfusion therapy [9]. The development of fibrinolytic 
agents has undergone an evolution from non-fibrin spe- 
cific agents (streptokinase and urokinase) administered 
via intravenous infusion, to infusions of fibrin-specific 
agents (tissue plasminogen activator [tPA]), to bolus only 
fibrin specific agents (rPA, TNK-tPA). The evolution of 
these fibrinolytic therapies was associated with incre- 
mental benefits to outcome. In the seminal GUSTO trial, 
tPA was first shown to have a mortality advantage over 
streptokinase [10]. Subsequently, reperfusion with TNK- 
tPA was associated with greater vessel patency than 
streptokinase, along with less systemic bleeding but 
similar mortality benefit as tPA [11]. An important ad- 
vantage conferred by TNK-tPA has been the ease of bo- 
lus administration, however, its use has not translated to 
further reductions in 30-day or late mortality compared 
to earlier generation fibrinolytics [11]. Nonetheless, its 
simpler dosage regimen does allow for wider application 
outside of hospital, more timely administration and fewer 
treatment errors. Studies have shown that the earlier ad- 
ministration of fibrinolysis is associated with greater 
benefit in preservation of left ventricular ejection fraction 
and reduction in mortality [12-14]. 
2.2. Failed Fibrinolysis 
Up to 40% of patients treated with fibrinolysis fail to 
achieve restored microvascular flow to the infarct terri- 
tory. This is defined by the persistence of chest pain and 
less than 50% reduction in ST-segment elevation at 90 
mins after fibrinolysis. The factors associated with failed 
pharmacological reperfusion include delay to presenta- 
tion and treatment, infarct location and concomitant the- 
rapies [15]. In the case of failed thrombolytic reperfusion, 
a strong body of evidence supports the role of emergent 
angiography and rescue PCI rather than re-administration 
of fibrinolytics [16]. Rescue PCI was shown by Gersh- 
lick et al. to be associated with lower rates of death, re- 
infarction, severe heart failure and stroke 6 months after 
STEMI compared to conservative therapy and repeated 
thrombolysis. The rate of event free survival at 6 months 
among patients treated with rescues PCI was 84.6%, as 
compared with 70.1% among those receiving conserva- 
tive therapy and 68.7% among those undergoing repeated 
thrombolysis (overall P = 0.004) [16]. Subsequently, a 
meta-analysis showed that rescue PCI was associated 
with improved clinical outcomes for STEMI patients 
after failed fibrinolytic therapy but the benefits is associ- 
ated with increased risk of stroke and minor bleeding 
compared to conservative strategy [17]. Other studies 
such as the ASSENT-4 PCI (Assessment of the Safety 
and Efficacy of a New Treatment Strategy with Percuta- 
neous Coronary Intervention) have assessed the role of 
routine emergency PCI after fibrinolysis, (also known as 
“facilitated PCI”) and found that this approach is associ- 
ated with an increase in the composite of death, heart 
failure and shock compared to primary-PCI alone (18.6% 
vs. 13.4%, P = 0.005) [18]. Similarly, the use of facili- 
tated PCI after administration of half dose r-PA and ab- 
ciximab (glycoprotein IIb/IIIa inhibitor) was also found 
not to improve outcome compared to primary PCI with 
administration of abciximab in the cath lab in the FI- 
NESSE (Facilitated Intervention for Enhanced Reperfu- 
sion Speed to Stop Events) trial [19].  
2.3. Primary Percutaneous Coronary  
Intervention  
Despite the clear benefits of fibrinolytic therapy com- 
pared with no reperfusion and its ease of use, there were 
still issues of both efficacy and safety that limits its use. 
These issues include: 
1) Normalisation of blood flow (as assessed by TIMI 
flow grade 3) occurs in only 50% - 60% of patients 
treated with fibrinolysis [10,20]. The clinical benefits of 
fibrinolytic therapy correlate only with restoration of 
TIMI grade 3 flow. 
2) High incidence (20% - 30%) of early recurrence of 
ischaemia with 5% - 15% [20,21] of frank fibrinolytic 
coronary reocclusion and reinfarction in 3% - 5% [22,23] 
despite initial apparent successful fibrinolysis. 
3) bMajor haemorrhagic complications occurring in 
2% - 3% of patients with the most serious being in- 
tracerebral haemorrhage which occurs in as many as 1% 
[24].  
4) There is a high proportion (20% - 30%) of patients 
particularly older adults who are not candidates for fi- 
brinolytic therapy because of contraindications such as 
active internal bleeding, a recent stroke or hypertension 
[25]. 
In the early 1990s, it was hypothesised that these prob- 
lems could be overcome by the use of primary-PCI. Al- 
though the implementation of primary-PCI requires more 
resources and is more difficult to quickly implement than 
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fibrinolysis studies have shown that when both methods 
of reperfusion are available, primary-PCI offer better 
clinical outcomes than fibrinolysis. In a meta-analysis 
that reviewed 23 randomised trials consisting of 7739 
patients, primary-PCI resulted in lower rates of stroke 
(1% vs. 2%, P = 0.004), early death (7% vs. 9%, P = 
0.0002) and non-fatal reinfarction (3% vs. 7%, P < 0.001) 
compared to fibrinolysis [14]. Nonetheless, these bene- 
fits of primary-PCI remain firmly dependent on timely 
implementation. Traditionally, this has been measured by 
“door-to-balloon time”, which represents the interval 
between presentation of the patient to hospital and the 
achievement of coronary artery patency by balloon an- 
gioplasty. Studies have demonstrated that the incremental 
gains from primary PCI are lost when door-to-balloon 
time and door-to-needle time (time from hospital arrival 
to initiation of fibrinolytic therapy) are greater than 60 
min and 114 min respectively [17,26,27]. Notably, rela- 
tive 1 year mortality rates increase by 7.5% for every 30 
minute delay in reperfusion [28]. Therefore efficient and 
effective clinical systems that are able to deliver timely 
and consistent reperfusion are required to preserve the 
advantage of primary-PCI over fibrinolysis. As reducing 
door-to-balloon time is crucial, strategies involving the 
performance of 12-lead ECG triage and emergency de- 
partment activation of primary-PCI have been proposed. 
A study including 349 patients showed that such a- 
straegy reduced the median door-to-balloon time from 98 
minutes to 56 minutes, compared to conventional strat- 
egy [29]. The key to achieving a balance between trans- 
fer for primary-PCI and fibrinolysis in hospitals without 
invasive services remains a challenge. Current guidelines 
recommend transfer for primary-PCI if the door-to-bal- 
loon time is expected to be less than 90 minutes. When 
this criterion can be satisfied, the DANAMI-2 study 
showed that transfer for primary-PCI results in lower 
rates of recurrent myocardial infarction, unplanned re- 
vascularisation and stroke compared to onsite fibrinoly- 
sis. However a reduction in mortality was not demon- 
strated [30]. 
2.4. In-Lab Strategies during Primary  
Percutaneous Coronary Intervention 
2.4.1. Antithrombotic Therapies 
In order to optimally restore myocardial perfusion during 
primary-PCI, effective antithrombotic therapies are re- 
quired.Unfractionated heparin (UFH) remains the most 
common antithrombotic therapy used with an initial in- 
travenous bolus of 70 IU/kg during primary-PCI. Recent 
studies have shown that low molecular weight heparin 
(LMWH) is better than UFH during primary-PCI. An 
open label ATOLL trial randomly assigned 901 STEMI 
patients to enoxaparin (intravenous bolus of 0.5 mg/kg) 
or UFH (initial intravenous bolus of 70 - 100 IU without 
or 50 - 70 IU with glycoprotein IIb/IIIa inhibitor) before 
primary-PCI [31]. There was no significant reduction in 
the rate of primary outcome of death, complication of MI, 
procedure failure or major bleeding with enoxaparin 
(28% vs. 34%; relative risk 0.83, 95% CI 0.68 - 1.01). 
The secondary end-point of death, recurrent MI or acute 
coronary syndrome, or urgent revascularisation however 
occurred significantly less often with enoxaparin (7% vs. 
11%; relative risk 0.59, 95% CI 0.38 - 0.91). Further-
more two meta-analyses have concluded that the use of 
LMWH (generally enoxaparin) compared to UFH leads 
to lower rates of mortality and major bleeding [32,33]. 
More recently bivalirudin, a short acting direct throm-
bin inhibitor, has emerged as alternative and possibly 
more efficacious antithrombotic therapy during primary- 
PCI. The HORIZONS AMI trial enrolled 3600 STEMI 
patients and randomised patients to either bivalirudin 
(initial bolus of 0.75 mg/kg followed by an intravenous 
infusion of 1.75 mg/kg per hour that was discontinued 
after PCI) plus provisional glycoprotein IIb/IIIa inhibitor 
or to UFH plus planned GP IIb/IIIa prior to primary-PCI. 
Patients treated with bivalirudin had reduced major 
bleeding (8.3% vs. 4.9%, P < 0.001). The 30 day cardiac 
mortality and total mortality were also reduced in the 
patients treated with bivalirudin (2.1% vs. 3.1%, P = 
0.047) [34].  
2.4.2. Parenteral Antiplatelet Therapies 
Abciximab, a chimeric monoclonal antibody fragment 
targeting the glycoprotein IIb/IIIa receptor, prevents 
platelet aggregation by blocking the binding of the GP 
IIb/IIIa receptor to fibrinogen, thereby inhibiting fi- 
brinogen-platelet bridging. It has been shown to be asso- 
ciated with a reduction in the composite endpoints of 
death, recurrent myocardial infarction and urgent revas- 
cularisation in patients undergoing primary-PCI [35-37]. 
However in the CADILLAC trial, the clinical benefit of 
abciximab in stented patients was not confirmed. It was 
observed that there was no difference in the rate of rein- 
farction or in left ventricular function at six months [38]. 
In a meta-analysis, abciximab therapy was associated 
with significant reductions in mortality at 30 days (2.4% 
vs. 3.4%, P = 0.047 with placebo) and six to twelve 
months (4.4% vs. 6.2%, P = 0.01) and in reinfarction at 
30 days (1.0% vs. 1.9%, P = 0.03); in addition there was 
no increase in bleeding. This analysis provides support 
for the concept that abciximab is beneficial in reducing 
acute ischemic events during primary PCI with stenting 
[39]. The intracoronary delivery of abciximab however 
has not been proven to be superior to intravenous ad- 
ministration in two recent randomised controlled trials 
[40,41]. Small molecule glycoprotein IIb/IIIa inhibitors 
(tirofiban and eptifibatide) have not been extensively 
studied but mechanistic studies have also suggested im- 
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proved vessel patency [42,43].  
2.4.3. Stents 
In patients treated with primary-PCI for STEMI, de- 
ployment of stents is now routine. The benefit of drug 
eluting stent (DES) platforms over bare metal stents 
(BMS) has been examined. In a meta-analysis that in- 
cluded thirteen clinical trials with 7244 STEMI patients, 
treatment with DES was associated with decreased target 
vessel revascularisation and myocardial infarction rates 
[44]. Furthermore, there was no increase in cardiac death 
or stent thrombosis occurrence with DES [44].  
2.4.4. Aspiration Thrombectomy 
Another recent development during primary-PCI is aspi- 
ration thrombectomy. Thrombus removal using aspira- 
tion thrombectomy devices (e.g. EXPORT catheter) has 
been recognised as a strategy that is associated with bet- 
ter epicardial and myocardial perfusion. This can be ex- 
plained by less distal embolisation of thrombus ordinar- 
ily resulting in microvascular damage. This was first 
shown by the TAPAS study which randomised 1071 pa- 
tients to conventional PCI vs. manual thrombus aspira- 
tion. Patients treated with thrombus aspiration had lower 
rates of myocardial blush grade 0 or 1 (17.1 vs. 26.3%, P 
< 0.001) [45]. In addition to myocardial perfusion meas- 
ures, a meta-analysis including nine randomised trials 
with 2417 patients also showed that adjunctive aspira- 
tion thrombectomy during primary-PCI is associated 
with a significant reduction in 30-day mortality [46].  
2.4.5. Reducing Bleeding Complications 
Patients treated with primary-PCI for STEMI are at in- 
creased risk of bleeding complications because they are 
concurrently managed with multiple antithrombotic and 
antiplatelet therapies. Bleeding complications have been 
linked with increased morbidity and mortality [47,48]. 
Studies have shown that reduction in bleeding complica- 
tions may lead to improved longer term clinical out- 
comes, including mortality [49,50]. A number of phar- 
macologic and procedural strategies can be employed to 
reduce the risk of bleeding associated with primary-PCI. 
The two main strategies that have been associated with 
reduction in bleeding complications and mortality are 
bivalirudin and radial artery access. Bivalirudin, a direct 
thrombin inhibitor, as previously discussed was shown in 
the HORIZONS AMI study to have reduced major 
bleeding and mortality in STEMI patients treated with 
primary-PCI. 
2.4.6. Radial versus Femoral Artery Access 
Important advances have been made in elective PCI with 
respect to reduced access site bleeding [51] and ultima- 
tely post-procedure mortality [52,53], through the advent 
of radial artery puncture compared to the traditional 
femoral artery approach. The RIFLE-STEACS (Radial 
Versus Femoral Randomised Investigation in ST-Eleva- 
tion Acute Coronary Syndrome) and RIVAL (A Trial of 
Trans-radial Versus Trans-Femoral Percutaneous Coro- 
nary Intervention (PCI) Access Site Approach in Patients 
With Unstable Angina or Myocardial Infarction Managed 
With an Invasive Strategy) studies explored the hypothe- 
sis that the safety associated with radial artery access 
may also translate into mortality benefit in STEMI pa- 
tients. In the latter study, Mehta and colleagues com- 
pared the efficacy and bleeding outcomes in patients with 
STEMI (n = 1958) and non STEMI (n = 5063) separately 
in those randomised to radial versus femoral arterial ac- 
cess. They found that radial artery access reduced the 
primary outcome (death/myocardial infarction/stroke/ 
non-coronary artery bypass graft related major bleeding) 
compared with femoral access in all-comers (3.1% vs. 
5.2%; hazard ratio [HR]:0.6; P = 0.026) while also re- 
ducing the rates of all-cause mortality at 30 days (1.3% 
vs. 3.2%; HR 0.39, P = 0.006) and the composite of 
death, myocardial infarction and stroke (2.7% vs. 4.6%; 
HR 0.59; P = 0.031) [54]. Interestingly, this effect on 
mortality outcome was specific for STEMI patients 
treated with primary PCI (1.4% radial vs. 3.1% femoral; 
HR: 0.46), as it did not apply to patients in the non- 
STEMI cohort (3.8% vs. 3.5%, P = 0.49), death/myo- 
cardial infarction / stroke (3.4% vs. 2.7%, P = 0.176) or 
all-cause mortality (1.3% vs. 0.8%, P = 0.082) [54]. 
Similar results were corroborated in the RIFLE-STEACS 
study, in which 1001 patients were randomised to radial 
(n = 500) and femoral (n = 501) approach at 4-high vol- 
ume centres between January 2009 and July 2011. The 
primary endpoint was the 30-day rate of net adverse 
clinical events (NACEs) defined as composite of cardiac 
death, stroke, myocardial infarction, target lesion revas- 
cularisation and bleeding. Radial access in patients with 
STEMI was associated with lower 30-day NACEs com- 
pared to femoral access (13.6% vs. 21%). In addition, 
radial access was also associated with significantly lower 
rates of cardiac mortality (5.2% vs. 9.2%), bleeding 
(7.8% vs. 12.2%, P = 0.026) and shorter hospital stay (P 
= 0.03) [55]. The results of these two studies highlight 
the safety, efficacy and benefit of radial arterial access 
during primary-PCI and herald its use as the preferred 
option in patients with STEMI, for interventional cardi- 
ologists who have adequate experience and expertise in 
radial approach.  
2.5. Oral Pharmacotherapies 
The evolution of our focus in modern treatment of 
STEMI to invasive management is fundamentally en- 
abled by the developments in antiplatelet and antithrom- 
botic therapies. Our improved understanding that plate- 
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lets play a central role in the development of STEMI has 
led to the use of more effective antiplatelet therapies 
which has been shown to be improve clinical outcomes. 
The greatest clinical challenge for the use of these phar- 
macotherapies is finding the balance between avoiding 
bleeding events and effective suppression of ischaemic 
events. 
2.6. Oral Antiplatelet Therapies 
Aspirin has been the mainstay treatment for all patients 
undergoing either pharmacological or primary-PCI. 
Therefore, all patients with acute coronary syndromes 
and without contraindications should receive aspirin 150 
- 300 mg [56].  
The second class of antiplatelet therapy is thienopyri- 
dine antagonist of ADP. It has been shown that patients 
younger than 75 years treated with fibrinolysis random- 
ised to receive clopidogrel (300 mg loading dose and 75 
mg daily compared with placebo) achieved improved 
rates of vessel patency 3 - 5 days later with a non-sig- 
nificant reduction in recurrent myocardial infarction 
(2.5% vs. 3.6%, P = 0.08) [57]. In addition, among 
45,852 patients treated for myocardial infarction, there 
was a 7% reduction in hospital mortality following the 
addition of clopidogrel (75mg a day added to aspirin, 
without loading dose) compared to placebo [58]. The 
issue of clopidogrel loading dose was recently evaluated 
in the CURRENT-OASIS 7 trial which assigned 25,086 
patients with ACS (29.2% STEMI) to either clopidogrel 
600 mg loading dose on day 1 followed by 150 mg daily 
for 6 days and 75 mg thereafter or clopidogrel 300 mg 
loading dose followed by 75 mg daily [59]. The rate of 
primary outcome (cardiovascular death, MI, or stroke at 
30 days) was not statistically different (4.2% vs. 4.4%, P 
= 0.3) between the two groups. Major bleeding occurred 
significantly more often in patients who received higher 
clopidogrel dose (2.5% vs. 2%, P = 0.01 in the overall 
population and 1.6% vs. 1.1%, P = 0.009 in the PCI sub- 
group). However, the higher dose of clopidogrel was 
associated with a significant reduction in the secondary 
outcome of definite stent thrombosis among patients who 
underwent PCI (0.7% vs. 1.3%, P = 0.0001).  
Prasugrel which irreversibly inhibits the P2Y12 recep- 
tor at the same site as clopidogrel was recently compared 
to clopidogrel in the TRITON-TIMI 38 trial of 13,608 
moderate to high risk ACS patients undergoing PCI, in- 
cluding 3534 STEMI patients [60]. In patients with 
STEMI at 15 month follow up, the primary efficacy 
endpoint of cardiovascular death, nonfatal MI or nonfatal 
stroke occurred significantly less often in patients treated 
with prasugrel (9.9% vs. 12.4%; HR 0.81; 95% CI 0.73 - 
0.9, P < 0.001), driven primarily by a significant reduc- 
tion in nonfatal AMI (7.4% vs. 9.7%, P < 0.001). In addi- 
tion, the rate of definite or probable stent thrombosis was 
also significantly reduced in the prasugrel group (1.6% 
vs. 2.8%, P < 0.001). However, a subset of patients had 
increased risk of bleeding, specifically those >75 years 
old, those <60 kg in weight and those with a history of 
prior stroke.  
Another antiplatelet agent, ticagrelor which blocks the 
P2Y12 receptor reversibly, has a more rapid onset of ac- 
tion than clopidogrel. Its efficacy in the treatment of 
STEMI has recently been studied in the PLATO trial. At 
12 months, the composite primary endpoint (death from 
vascular causes, MI, or stroke) occurred significantly less 
often in patients receiving ticagrelor (9.8% vs. 11.7% 
with clopidogrel, HR 0.84, 95% CI 0.77 - 0.92, P < 
0.001). There was no significant difference in the rates of 
major bleeding between the two groups (11.6% and 11.2%, 
respectively; P = 0.43), but ticagrelor was associated 
with a significantly increased risk of major bleeding not 
related to CABG (4.5% vs. 3.8%, P = 0.03). In addition, 
the secondary endpoints of the rates of myocardial in- 
farction (5.8% vs. 6.9%, P = 0.005), death from vascular 
causes (4.0% vs. 5.1%, P = 0.001), and death from any 
cause (4.5% vs. 5.9%; P < 0.001) were all significantly 
lower in the ticagrelor group [61]. 
Taken together, there is compelling evidence for the 
use of dual therapy with aspirin and complementary an- 
tiplatelet agents. The relevant data apply both to the 
overall management of patients with STEMI and fur- 
thermore to the primary PCI setting. Although recent 
results indicate that prasugrel and ticagrelor may have an 
advantage over clopidogrel, individual patient criteria 
relating to the risk of bleeding must be taken into con- 
sideration before selecting a regime. Furthermore, the 
cost and availability of newer agents would also be a 
consideration. 
In summary, the combination of antiplatelet and anti- 
thrombotic therapies needs to strike a balance between 
optimising ischaemic outcomes, while reducing bleeding 
risk.  
1) In general, all patients should receive dual anti- 
platelet agents (aspirin and Clopidogrel, Prasugrel or 
Ticagrelol) and one antithrombin agent (unfractionated 
heparin, enoxaparin, bivalirudin or fondaparinux, but not 
a combination). 
2) In patients with increased risk of bleeding and inva- 
sive strategy is planned, use of bivalirudin is supported 
by strong data [34]. 
3) In patients with increased risk of bleeding and con- 
servative management is planned, fondaprinux is associ- 
ated with reduced bleeding and mortality [62]. 
There is evidence to support the additive benefits of 
combination antiplatelet agents (aspirin, thienopyridines, 
and glycoprotein IIb/IIIa inhibition). 
4) For patients with elevated troponin levels undergo- 
ing PCI, abciximab in addition to clopidogrel and aspirin 
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further reduces ischaemic events [63]. This should be 
commenced in the catheterisation laboratory rather than 
soon after admission as this has been shown to reduce 
major bleeding [64].  
Further studies are ongoing to help further our under- 
standing in this area and will help refine our approach. 
2.7. Secondary Risk Prevention after Acute  
Myocardial Infarction 
Following successful reperfusion therapies after acute 
myocardial infarction, secondary risk prevention includ- 
ing optimal blood pressure control, aggressive lipid low- 
ering therapy, smoking cessation, weight reduction, ex- 
ercise and participation in a cardiac rehabilitation pro- 
gramme are important for improving outcomes. In a 
meta-analysis by Clark et al. on secondary risk preven- 
tion programmes, clear sustained mortality benefit (risk 
ratio 0.85, 95% CI 0.77 - 0.94) was associated with these 
programmes [65]. Further reductions in ischaemic events 
are associated with aspirin and clopidogrel. Therefore 
aspirin should be continued indefinitely and for clopido- 
grel at least 3 - 12 months. The CURE trial demonstrated 
that the evidence of benefit from clopidogrel begin to 
emerge within 24 hours and sustained benefit was ob- 
served up to 12 months in patients with acute coronary 
syndrome [66]. Angiotensin converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers has a role 
in patients with heart failure, anterior infarction or his- 
tory of previous infarction. Besides blood pressure con- 
trol, these agents also have a role in reducing left ven- 
tricular remodelling [67-69]. In patients with an ejection 
fraction of less than 40% without severe renal dysfunc- 
tion or hyperkalaemia, aldosterone antagonist has mor- 
tality benefit and should be considered [70]. The benefit 
of lipid lowering post acute myocardial infarction is well 
understood. Patients should be counselled on non-phar- 
macologic therapy such as exercise, weight reduction 
and dietary modification. The role of statin therapy, in 
particular high dose statins, at the time of diagnosis pro- 
vides substantial reductions in mortality as well as non- 
fatal ischaemic events [71]. Beta-blockers are also rec- 
ommended after acute myocardial infarction with bene- 
ficial effects on fewer recurrent myocardial infarctions 
and episodes of ventricular fibrillation. However this 
benefit has also been associated with increased risk of 
cardiogenic shock [72]. In patients with severe left ven- 
tricular dysfunction post acute myocardial infarction, 
long acting beta-blockers such as bisoprolol, carverdilol 
and metoprolol succinate should be considered. In the 
CAPRICORN trial, carvedilol compared to placebo was 
associated with lower all cause and cardiovascular mor- 
tality when prescribed to patients with left ventricular 
systolic dysfunction defined by EF < 40% [73]. 
3. CONCLUSION 
Significant reductions in in-hospital, intermediate and 
long-term outcomes in patients afflicted with acute myo- 
cardial infarction have occurred as a result of the additive 
benefits of prompt mechanical revascularisation strate- 
gies coupled with the administration of up-stream anti- 
thrombotic and anti-platelet therapies. Newer anti-plate- 
let agents have impacted upon rates of stent thrombosis, 
however, at the expense of increased bleeding rates. It is 
likely that a personalised approach to the chronic mana- 
gement of thrombotic and bleeding risk in patients’ post- 
AMI will yield optimal patient outcomes. 
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